“Antibiotic research and development need an urgent boost now more than ever, and GARDP is part of the solution. As a GARDP Board Observer, I am honored to support GARDP in its efforts to ensure new and effective treatments.”

 

– Hanan H. Balkhy, Assistant Director-General, Antimicrobial Resistance, WHO

Four programs to address drug resistance


Discovery and
exploratory

GARDP’s discovery and exploratory program focuses on three activities to advance antibiotic R&D: discovery and exploratory research; asset evaluation and development; and scientific affairs and REVIVE.


Children’s
antibiotics

Every year 3 million babies and 1.2 million children suffer from sepsis, a life-threatening complication of infection. Three out of every ten neonatal sepsis deaths result from drug-resistant bacteria. GARDP is developing new treatments and generating evidence to support the use of existing antibiotics in babies and children.

Sexually transmitted
infections

Infection rates of gonorrhea are increasing, with 82 million new cases each year worldwide. This infection—which can lead to infertility, ectopic pregnancy, and increased risk of HIV transmission—has progressively developed resistance to available treatments. GARDP is supporting the late-stage trial of a new treatment for gonorrhea.

Serious bacterial
infections

Serious bacterial infections are among the leading cause of death for people in hospitals. Drug resistance is making these infections increasingly difficult to treat. GARDP is working on treatments for these infections, prioritizing those caused by the bacteria most impacted by antibiotic resistance.

REVIVE: Education & Collaboration

GARDP created REVIVE to improve, accelerate, and streamline drug discovery and research and development by directly connecting researchers with established and retired antibiotic researchers and developers, and by facilitating learning and knowledge exchange.

Action to address antibiotic resistance

Why we must act: Stories of drug resistance

“Antibiotic resistance is a major problem. It breaks my heart to see a baby dying when an antibiotic hasn’t worked.‍ We are running out of options. If we don’t get more antibiotics on board, more babies are going to die.”

by Dr. Tanusha Ramdin (Senior Neonatalogist)

“We are running out of antibiotics that work. We haven’t invested in finding new ones, while the old ones are failing more by the day.”

by Vanessa Carter (Patient advocate for antibiotic resistance)

“My hope is that one day disease intervention specialists will not need to have to track down partners of someone who tested positive for an STI, to get them tested and treated, only because there are no more sexually transmitted infections.”

by Melissa Nelson (Disease Intervention Specalist )

“Not only were patients battling with COVID, they then had to face a secondary infection, which could often not be treated because of antibiotic resistance.”

by Chelsea Kruger (medical doctor and researcher)